58578-44-2

Basic information

• Product Name: benzyl L-2-<(carbobenzxyloxy)amino>-4-hydroxybutyrate
• Synonyms: benzyl L-2-<(carbobenzxyloxy)amino>-4-hydroxybutyrate
• CAS NO: 58578-44-2
• Molecular Weight: 343.379
• Mol File: 58578-44-2.mol
• Article Data: 18

Chemical Properties

• CAS DataBase Reference: benzyl L-2-<(carbobenzxyloxy)amino>-4-hydroxybutyrate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl L-2-<(carbobenzxyloxy)amino>-4-hydroxybutyrate(58578-44-2)
• EPA Substance Registry System: benzyl L-2-<(carbobenzxyloxy)amino>-4-hydroxybutyrate(58578-44-2)

Safety Data

• Hazardous Substances Data: 58578-44-2(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 58578-43-1 (S)-2-benzyloxycarbonylamino-4-hydroxybutyric acid dicyclohexylamine salt 
• 501-53-1 benzyl chloroformate 
• 35677-89-5 benzyl (3S)-2-oxotetrahydro-3-furanylcarbamate 
• 4779-31-1 Z-Asp-OBn 
• 35677-88-4 N-benzyloxycarbonyl-(L)-homoserine 

Downstream Products

• 1213783-55-1 (S)-benzyl 2-(benzyloxycarbonylamino)-4-methoxybutanoate 
• 1338593-96-6 C₂₇H₂₄N₂O₇ 
• 1338593-97-7 C₃₈H₃₅ClN₂O₅ 
• 144876-97-1 2(S)-2-(benzyloxycarbonylamino)-4-iodobutyric acid benzyl ester 
• 95656-90-9 (S)-2-Benzyloxycarbonylamino-4-bromo-butyric acid benzyl ester 

Relevant articles and documents

Diaminodiacid bridge improves enzymatic and in vivo inhibitory activity of peptide CPI-1 against botulinum toxin serotype A

The replacement of the disulfide bridge of CPI-1, a peptide inhibitor of light chain of Botulinum toxin serotype A, with the thioether-containing and biscarba-containing diaminodiacid bridge leads to a significant decrease in the degradation by trypsin and increase in the detoxification activity in vivo, the addition of hydrophobic or positive amino acid at C-terminus of modified peptides further improves the inhibitory activity.

HERBICIDAL CINNOLINIUM COMPOUNDS

Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.

CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv- containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.